Back to Discover

ANAB · Biotech · Nasdaq · As of 21 Nov 2026

Anaptysbio, Inc stock: filings, catalysts and timeline

Sign in to follow

AIR Score

0100
54

Neutral · 54 / 100

AIR confidence

Support behind the full AIR read.

What is this? →

How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.

The Discovery Gap

LOWHIGHVERY HIGH

High

Gap confidence

How fully AIR could measure this Gap — separate from the AIR Score's confidence.

What is this? →

How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.

Five perspectives

  • FundamentalsWhat is this?Too few of the required measures on file

    How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.

    Source: SEC XBRL financial statements.

  • ValueWhat is this?Too few of the required measures on file

    How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.

    Source: SEC XBRL financial statements and end-of-day prices.

  • News flowWhat is this?Balanced

    What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.

    Source: SEC EDGAR 8-K filings and FDA approvals.

  • MomentumWhat is this?Watch

    The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.

    Source: End-of-day prices.

  • SafetyWhat is this?Strong

    The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.

    Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.

Rating words, not raw numbers.

How AIR scores →

Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on News flow, Momentum and Safety, and the missing score lowers its AIR confidence.

Discovery Gap: High (36/100) · Gap confidence 52/100

Discovery gap

Filings show more traction than the tape reflects.

Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.

What is this?

How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.

Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.

How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.

This month at a glance

AIR Score™ change: +1Moved up +1 on new evidence.
Window31 Oct 2026 → 21 Nov 2026
Safety+1Lifted the score this month.

Evidence timeline

What changed — last 90 days

As of 13 Nov 2026
  1. The company reported Q1 FY2027 results with Jemperli achieving $1.0B in nine-month sales and 29% YoY growth, and FDA approval in rectal cancer.

    Results · 8-K filed 12 Nov →

  2. The company filed its quarterly report for the period ending 30 September 2026.

    Quarterly/annual report · 10-Q filed 12 Nov →

What the company disclosed, not verified by AIR · sources link to the Evidence timeline below.

  1. Expected
  2. Wed 3 Mar · expected 10-K

    Last year filed 3 Mar 2026.

  3. Wed 12 May · expected 10-Q

    Last year filed 12 May 2026.

  4. Filed
  5. Thu 12 Nov · 10-Q

    Quarterly report (10-Q), period ending 30 Sep 2026

    Gap High · 28 → High · 39

    Progress is running ahead of attention.

  6. Thu 12 Nov · 8-K

    8-K · Item 2.02 — Results of operations

    AnaptysBio reported Q1 FY2027 results with Jemperli achieving $1.0B in nine-month sales (29% YoY growth) and FDA approval in rectal cancer. Litigation with GSK/Tesaro post-trial hearing held; judgment expected Q4 2026/Q1 2027. Quimilza FDA decision due December 2026.

    Gap High · 28 → High · 39

    Progress is running ahead of attention.

  7. Mon 21 Sep · 8-K

    Current report (8-K)

  8. Tue 11 Aug · 8-K

    Current report (8-K)

  9. Thu 30 Jul · 8-K

    Current report (8-K)

  10. Mon 22 Jun · 8-K

    8-K · Item 1.01 — Material agreement

  11. Fri 29 May · 8-K

    Current report (8-K)

  12. Thu 21 May · 8-K

    Current report (8-K)

  13. Tue 12 May · 10-Q

    Quarterly report (10-Q), period ending 31 Mar 2026

  14. Tue 12 May · 8-K

    8-K · Item 2.02 — Results of operations

  15. Mon 11 May · 8-K

    8-K · Item 5.02 — Director or officer change

  16. Mon 20 Apr · 8-K

    8-K · Items 1.01, 2.01, 5.02, 8.01 — Material agreement

  17. Fri 27 Mar · 8-K

    8-K · Items 1.01, 1.02, 5.02 — Material agreement

  18. Tue 3 Mar · 10-K

    Annual report (10-K), FY2025

  19. Tue 3 Mar · 8-K

    8-K · Item 2.02 — Results of operations

  20. Fri 9 Jan · 8-K

    8-K · Item 2.02 — Results of operations

  21. Wed 26 Nov · 8-K

    Current report (8-K)

  22. Fri 21 Nov · 8-K

    8-K · Item 8.01 — Other events

  23. Fri 21 Nov · 8-K

    8-K · Item 8.01 — Other events

  24. Mon 10 Nov · 8-K

    8-K · Item 8.01 — Other events

  25. Tue 4 Nov · 8-K

    8-K · Item 2.02 — Results of operations

  26. Tue 4 Nov · 10-Q

    Quarterly report (10-Q), period ending 30 Sep 2025

  27. Tue 14 Oct · 8-K

    Current report (8-K)

  28. Mon 29 Sep · 8-K

    8-K · Item 8.01 — Other events

Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.

Ask AIR

What would change our view

A weaker balance sheet in the next filing cycle, a material regulatory setback, or attention arriving — which closes the gap by design would move the score, and the page would show which one did.

Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.